Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANCNNASDAQ:BNTCNASDAQ:IMRNOTCMKTS:MCUJFNASDAQ:NVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$0.66-1.5%$21.77$0.51▼$10.55$4.89M0.933.15 million shs11,539 shsBNTCBenitec Biopharma$6.90+2.7%$5.06$1.86▼$9.01$17.87M1.0367,063 shs28,676 shsIMRNImmuron$2.49$5.04$1.92▼$28.99$14.19M1.4322,166 shs3,424 shsMCUJFMedicure$0.74-7.4%$0.82$0.68▼$1.26$7.73M0.923,880 shs7,300 shsNVUSNovus Therapeutics$1.97-8.8%$13.23$4.50▼$27.32$2.83M2.0778,851 shs100,805 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics+1.53%+1.41%-7.84%+34.00%-57.05%BNTCBenitec Biopharma-2.04%+40.00%+33.33%+128.57%+79.76%IMRNImmuron-1.58%+3.32%-4.60%+34.59%+16.90%MCUJFMedicure+17.54%+0.58%+4.58%-20.11%-16.89%NVUSNovus Therapeutics-2.48%+25.48%-4.83%+8.84%-13.22%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABNTCBenitec Biopharma1.5936 of 5 stars3.53.00.00.02.30.80.0IMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano TherapeuticsN/AN/AN/AN/ABNTCBenitec Biopharma3.00Buy$16.00131.88% UpsideIMRNImmuronN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest NVUS, IMRN, ANCN, MCUJF, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.002/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ABNTCBenitec Biopharma$80K223.39N/AN/A$0.12 per share57.50IMRNImmuron$1.22M11.63N/AN/A$2.32 per share1.07MCUJFMedicure$16.07M0.48$0.10 per share7.67$1.41 per share0.52NVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.464.39N/AN/AN/A36.08%27.40%N/ABNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)IMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AMCUJFMedicure-$680K-$0.06N/A∞N/A-4.17%-4.29%-3.14%5/24/2024 (Estimated)NVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/ALatest NVUS, IMRN, ANCN, MCUJF, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MCUJFMedicureN/A-$0.10-$0.10-$0.10N/A$3.73 million2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25BNTCBenitec Biopharma0.013.623.62IMRNImmuronN/A8.527.79MCUJFMedicure0.011.921.55NVUSNovus TherapeuticsN/A18.7818.78OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%BNTCBenitec Biopharma52.19%IMRNImmuron0.12%MCUJFMedicureN/ANVUSNovus TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%BNTCBenitec Biopharma4.30%IMRNImmuron7.01%MCUJFMedicure12.90%NVUSNovus Therapeutics2.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataIMRNImmuronN/A5.70 million5.30 millionNot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableNVUS, IMRN, ANCN, MCUJF, and BNTC HeadlinesSourceHeadlineVivoryon Therapeutics NV VVYmorningstar.com - March 1 at 10:37 PMViking Therapeutics Incmoney.usnews.com - February 22 at 8:11 PMCYT Cyteir Therapeutics, Inc.seekingalpha.com - December 28 at 2:55 PMNovo Holdings invests in US$105 million Series C Funding of Alentis Therapeuticsfinance.yahoo.com - May 11 at 10:47 AMProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, Predictionsbenzinga.com - March 31 at 6:04 PMSales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR Analysisfinance.yahoo.com - March 30 at 3:52 PMChimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T studyproactiveinvestors.com - March 29 at 8:06 AMEast Career Technical Academyusnews.com - March 25 at 6:58 PMLas Vegas Academy of the Artsusnews.com - March 25 at 6:58 PMAbout Us – Hartford Courantcourant.com - March 5 at 9:27 AMPerspective Therapeutics Incmoney.usnews.com - February 22 at 3:24 PMOnychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGRfinance.yahoo.com - February 12 at 1:14 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnchiano TherapeuticsNASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.MedicureOTCMKTS:MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.